October 29, 2025 — Leads & Copy — PURE Bioscience, Inc. (OTCQB: PURE) today reported its fiscal year-end results for July 31, 2025.
Net product sales increased to $2,198,000, up from $1,955,000 in 2024, driven by increased sales across its end-user and distribution network. Net loss decreased to ($2.4 million) from ($3.4 million) due to reduced personnel, facility, and board fees.
In fiscal year 2025, PURE revitalized its brand and focused on sanitation and safety in food and beverage manufacturing. The company piloted Ultra-Filtration (UF) and Reverse Osmosis (RO) systems with a California State University Dairy Pilot Processing Center, paving the way for a commercial launch of a next-generation membrane treatment.
A new distribution agreement with Hydrite Chemical Company and a strategic partnership with Bonsai expanded PURE’s reach. The company is investing in targeted marketing and R&D partnerships to develop advanced cleaning and sanitization solutions.
CEO Robert Bartlett said the company expanded its core business by 14% and developed a new solution for treating membranes in the dairy and beverage industries.
PURE is committed to redefining chemical safety through its innovative technology. With a focus on efficacy and effectiveness, PURE develops advanced solutions that meet the highest safety standards and produce best-in-class results for its consumers and distributors.
Contact:
Robert Bartlett, Chief Executive Officer
Source: PURE Bioscience, Inc.
